

Drug(s)	Trial Name	NCT / WHO #	Arms	Ph	N	Group(s)	Status	Results
Rifamycins: Rifampentine - P - RPT (Sanofi)								
TBTC 29X	NCT00694629	2HPZE (20 v. 15 v. 10 mg/kg/d) v. 2HRZE	II	320	TBTC (Dorman)	Results ATS 2013, AJRCCM 2015	1200 mg P safe/tolerable, flat dosing better	
RIFAQUIN	ISRCTN44153044	2MRZE/2M ₂ P ₂ 900 v. 2MRZE/4M ₁ P ₁ 1200 v. 2HRZE/4HR	III	1095	MRC/UK, EDCTP	Results IUATLD 2013, NEJM Oct 2014	4 mo inferior, 6 mo non-inferior, both safe/tolerable	
RioMAR	NCT00728507	2HP ₂ ZM v. 2HRZE (P = 7.5 mg/kg)	II	216	JHU (Dorman)	Results CROI 2014 93, PLoS One May 2016	Early stop 56% accrual, HPZM better by liquid media	
A5311	NCT01574638	P 15 mg/kg v. 20 mg/kg qd or bid ± egg [HIV- healthy volunteers]	I	48	ACTG (Dooley)	Results CROI 2014 816, AAC 2015	Higher AUCs/intolerance w/doses up to 1800 mg	
Sanofi	NCT01690403	21d pK P 600 mg q wk + Atripla [HIV+ healthy volunteers]	I	36	Sanofi	Results CROI 2014 493	EFV 600 mg OK with once-weekly P (10 mg/kg)	
FDA Cape Town Trial	NCT00814671	2P ₂ (600 v. 450 mg) HZE v. 2HRZE	II	153	JHU (Dorman/Dawson)	Results IUATLD 2014	Safe/tolerable but no difference cx conversion	
A5279	NCT01404312	LTBI: HP (10 mg/kg) qd x30d pK substudy: P + EFV [HIV+]	III	3000	ACTG (Chaisson)	pK Results CROI 2014 105, results Q1 2018	EFV OK with daily P (10 mg/kg)	
TBTC 31 / A5349	NCT02410772	2HP ₁₂₀₀ ZE/2HP v. 3HP ₁₂₀₀ ZM ₄₀₀ v. 2HRZE/4HR [HIV-/-, ages 13 and up, sparse PK]	III	2500	TBTC/ACTG	Opened Jan 2016, enroll thru Q4 2018	Includes DDI PK P/EFV in 31 + 90 HIV+ in 2 stages	
TBTC 31 / A5349 PK	NCT02563327	Intense PK: 2HP ₁₂₀₀ ZE/2HP v. 3HP ₁₂₀₀ ZM ₄₀₀ v. 2HRZE/4HR [HIV-/-]	II	60	TBTC/ACTG	Opened Jan 2016, enroll thru Q4 2018	Intensive PK P, M	
IMPAACT 2001	NCT02651259	LTBI PK/safety: HP (10 mg/kg) q wk x 12 [pregnant/postpartum, ≥ 18 yrs, HIV-/-]	II/III	82	IMPAACT (Mathad)	Opened Feb 2017, enroll thru Q1 2018		
CORTIS	NCT02735590	LTBI: 3HP ₉₀₀ weekly v. no intervention [↑risk by transcriptomics, HIV- adults]	III	3200	UCT (Hatherill)	Opened July 2016, results 2018	15 month follow-up	
WHIP3TB	NCT02980016	LTBI: 3HP weekly Y1 v. 3HP weekly Y1&Y2 v. 6H Y1 daily	III	4000	Aurum Inst. (Churchyard)	Opened Nov 2016, results Sep 2019		
TBTC 35	n/a	LTBI PK/safety: P (25-35 mg/kg) + H (10-15 mg/kg) in ages <2, 2-5, 6-12 [HIV-/-]	II	80	TBTC/Sanofi (Hesseling)	Opens Q2 2017 (pending IND/sponsor issues)	New water dispersible tablet co-formulation	
Rifamycins: High-dose Rifampin - R - RIF								
HIGHRIF1	NCT01392911	2 wk max tolerability dosage, PK, EBA R to 35 mg/kg	EBA	68	EDCTP/PanACEA	Results IUATLD 2013, AJRCCM Feb 2015	35 mg/kg safe/tolerable, no gr4/5 events, min LFT ↑	
RIFATOX	ISRCTN55670677	2HRZE with R 20 v. 15 v. 10 mg/kg	II	300	St. George's/INTERTB	Results IUATLD 2013, IJLTD Jun 2016	20 mg/kg safe/tolerable, dose-related ↑ LFTs < gr3	
HIGHRIF2	NCT00760149	2R 1200 (20 mg/kg) v. 900 (15 mg/kg) v. 600 (10 mg/kg)	II	150	EDCTP/PanACEA	Results InterTB Oct 2014	15 + 20 mg/kg safe/tolerable, pK variability	
MAMS-TB-01	NCT01785186	HR ₃₅ ZE v. HRZQ v. HR ₂₀ ZQ v. HR ₂₀ ZM v. HRZE	II	368	EDCTP/PanACEA	Results CROI 2015 95LB, Lancet ID 2017	TTCC R ₃₅ < R ₂₀ at 12wk MGIT only, ↑ liver AEs R ₃₅	
n/a	NCT02387242	WBA: R (30 mg/kg) v. R (20 mg/kg) [healthy]	II	18	NUH Singapore (Paton)	Opened Feb 2015, results Sep 2015		
HIRIF	NCT01408914	2HR ₁₂₀₀ ZE v. 2HR ₉₀₀ ZE v. 2HR ₆₀₀ ZE	II	180	Harvard (Mitnick)	Results Apr 2016		
RIFAVIRENZ	NCT01986543	2R (20 mg/kg)HZE + EFV 600 or 800/d v. 2R (10 mg/kg)HZE + EFV 600/d	II	105	ANRS	Results Apr 2017		
RIFASHORT	NCT02581527	2HR ₁₂₀₀ ZE/2HR ₁₂₀₀ v. 2HR ₁₈₀₀ ZE/2HR ₁₈₀₀ v. 2HRZE/4HR [HIV-]	III	820	St. George's/INTERTB	Opened Feb 2017, results Jan 2020		
Rifamycins: Rifabutin - B - RBT								
EARNEST Substudy	NCT01663168	pK Safety B ₃ v. B ₇ + LPV/r (24 wks) [HIV+ on ART]	II	140	MRC/UK (Uganda sites)	pK substudy results pending		
A5290	NCT01601626	2HBZE/4RH + LPV/r 200 mg +/- RAL vs. 2HRZE/4RH + LPV/r 400 mg	II	71	ACTG (Benson)	Stage 1 results IAS 2017		
APT	NCT02256696	12 wk: 2Pa ₂₀₀ BHZ/1Pa ₂₀₀ BH v. 2Pa ₂₀₀ RHZ/1Pa ₂₀₀ RH v. 2HRZE/1HR [DS]	II	183	JHU (Dooley/Dawson)	Accrual 28, reopening May 2017 after Pa hold		
TB Host-Directed Rx	NCT02968927	2HBZE/4BH +/- Everolimus v. Auranofin v. VitD3 v. CC11050 (PDE4inh) [DS, HIV-]	III	200	Aurum Inst. (Wallis)	Opened Nov 2016, results Mar 2018		
A5289	n/a	2-stage dose-range open label: HRZU v. HBZU v. HRZE [DS only] [HIV-/+]	II	182	ACTG (Luetkemeyer)	On hold (Sep 2016)		
Nicotonic Acids: High-dose Isoniazid - H - INH								
A5312	NCT01936831	1 wk EBA H 15 v. 10 v. 5 mg/kg/d in INH-A resistant TB	EBA	265	ACTG (Dooley/Diacon)	N=227, results Q3 2018		
Fluoroquinolones: Levofloxacin - Lx, Gatifloxacin - G - Gx, Moxifloxacin - M - Mx								
RIFAQUIN	ISRCTN44153044	2RMZE/2M ₂ P ₂ 900 v. 2RMZE/4M ₁ P ₁ 1200 v. 2HRZE/4HR	III	1095	MRC/UK, EDCTP	Results IUATLD 2013, NEJM Oct 2014	4 mo inferior, 6 mo non-inferior, both safe/tolerable	
OFLOTUB	NCT00216385	2HRZG/2RHG v. 2HRZE/4HR	III	1836	EU/WHO	Results IUATLD 2013, NEJM Oct 2014	4 mo inferior, both arms safe/tolerable	
RioMAR	NCT00728507	2HP ₂ ZM v. 2HRZE (P = 7.5 mg/kg)	II	216	JHU (Dorman)	Results CROI 2014 93, PLoS One May 2016	Early stop 56% accrual, HPZM better by liquid media	
RemOX	NCT00864383	2HRZM/2HRM v. 2RMZE/2RM v. 2HRZE/4HR	III	1931	TB Alliance/PanACEA	Results ICAAC 2014, NEJM Oct 2014	4 mo arms inferior, both safe/tolerable	
MAMS-TB-01	NCT01785186	HR ₃₅ ZE v. HRZQ v. HR ₂₀ ZQ v. HR ₂₀ ZM v. HRZE	II	372	EDCTP/PanACEA	Results CROI 2015 95LB, Lancet ID 2017	HRZQ + HR ₂₀ ZQ arms dropped Mar 2014	
A5307	NCT01589497	2 wk EBA RMZE v. RZE v. HRZE	EBA	69	ACTG (Bishai)	Completed Feb 2016, results CROI 2017 79	INH had no EBA, even by D2 (? Lower load sputa)	
STREAM Stage 1	ISRCTN78372190	4MCEZHkPro/5MCZE v. local DR regimen [DR]	III	400	IUATLD/MRC/DFID/USAID	Closed to accrual Jun 2015, results Q2 2018		
NC-006 STAND	NCT02342886	4Pa _{100/200} MZ v. 6Pa ₁₀₀ MZ v. 6Pa ₂₀₀ MZ v. 2HRZE/4HR [DS, DR 6Pa ₂₀₀ MZ only]	III	284	TB Alliance	Completed early, results Q3 2017		
OPTI-Q	NCT01918397	Lx (14 v. 17 v. 20 mg/kg/d) + OBT v. Lx (11 mg/kg/d) + OBT [DR]	II	100	NAID/TBTC (Horsburgh)	Accrual completed, results Q3 2016		
NexGen EBA	NCT02371681	4 wk EBA: 1MRHZ [serial F-DG PET scans, DS only]	II	350	NAID (Barry/PET)	Opened Jan 2015, results Nov 2017		
NEt-5001	NCT02454205	6-9LzJLzZ(H or Eth or Ter) v. 6-8KMZ(Eth or Ter)/16-18MZ(Eth or Ter) [DR]	II/III	300	UCT/Stellenbosch (Dheda)	Opened Oct 2015, results Jan 2019		
TBTC 31 / A5349	NCT02410772	2HP ₁₂₀₀ ZE/2HP v. 3HP ₁₂₀₀ ZM ₄₀₀ v. 2HRZE/4HR [HIV-/-, ages 13 and up, sparse PK]	III	2500	TBTC/ACTG	Opened Jan 2016, enroll thru Q4 2018	Includes DDI PK P/EFV in 31 + 90 HIV+ in 2 stages	
TBTC 31 / A5349 PK	NCT02563327	Intense PK: 2HP ₁₂₀₀ ZE/2HP v. 3HP ₁₂₀₀ ZM ₄₀₀ v. 2HRZE/4HR [HIV-/-]	II	60	TBTC/ACTG	Opened Jan 2016, enroll thru Q4 2018		
MDR-END	NCT02619994	9 or 12D + Lx _{750/1000} + Lz _{600/2M+300} + Z v. 24OBR [DR, quinolone sensitive]	II	238	Seoul Nat. Univ. Hospital	Opened Jan 2016, results Dec 2019		
TB-PRACTECAL	NCT02589782	2 stage: 6JPaMLz v. 6JPaLzC v. 6JPaLz v. 24OBR [DR, XDR]	II/III	630	MSF Holland/UCL/LSHTM	Opened Jan 2017, results Mar 2021	Belarus, South Africa, Uzbekistan	
STREAM Stage 2	NCT02409290	MCEZHkPro v. JLvCEZHPro v. JLvCZHK v. local DR regimen [DR]	III	1155	IUATLD/MRC/USAID/TBA	Opened Apr 2016, results Apr 2021		
endTB	NCT02754765	9JLzMZ v. 9JLzCLzZ v. 9JLzDLzZ v. 9DCMZ v. 24OBR [DR, quinolone sensitive]	III	750	MSF France/Harvard	Opened Dec 2016, results Sep 2020	Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru	
V-QUIN MDR	ACTRN1260002154	LTBI: 6Lx _{250/500/750} v. placebo (blinded) [DR contacts, ≥15 rand/screen all, HIV+/-]	III	2006	Australia NHMRC (Fox)	Opened 2016, results 2019	Vietnam (multiple sites)	
TB-CHAMP	n/a	LTBI: 6Lx _{15-20 mg/kg/d} v. placebo (blinded) [DR contacts, ages 0-5, HIV+/-]	III	1565	MRC/DFID/Wellcome	Opens 2017, results 2019	South Africa (Stellenbosch and 3 other sites)	
Diarylquinolines: Bedaquiline - TMC-207 - J (Janssen/TB Alliance)								
n/a	NCT01341184	pK single dose J + RFB, J + RFM [healthy volunteers]	I	32	NAID (CWRU)	Completed 2012, results pending		
NC-003	NCT01691534	2 wk EBA JPaZ, JPaZC, JPaC, JZC, Z, C	Ila	105	TB Alliance	Results CROI 2014 97LB, AJRCCM Jan 2015	BPaz best, mod QT effect, C no activity	
NC-005	NCT02193776	SSCC: J(400 mg/d x14d, 200 mg tiw)/PaZ v. J(200 mg/d)/PaZ (+ M in DR) v. HRZE	Ilb	240	TB Alliance	FU to M24 ongoing, results CROI 2017 LB724	BPazM + BPaz had highest BA; low AEs in 8 wks	
n/a	NCT02366523	single arm pK/safety Japanese: 6J + OBR [DR]	II	5	Janssen	Opened Feb 2015, follow-up thru Nov 2018		
NIX-TB	NCT02333799	6JPa ₂₀₀ LZD (600 mg bid) [single arm, XDR]	II	200	TB Alliance	Opened Mar 2015, primary results Oct 2018	Interim results CROI 2017 80LB, effective, 27% AEs	
NEt-5001	NCT02454205	6-9LzJLzZ(H or Eth or Ter) v. 6-8KMZ(Eth or Ter)/16-18MZ(Eth or Ter) [DR]	II/III	300	UCT/Stellenbosch (Dheda)	Opened Oct 2015, results Jan 2019		
TB-PRACTECAL	NCT02589782	2 stage: 6JPaMLz v. 6JPaLzC v. 6JPaLz v. 24OBR [DR, XDR]	II/III	630	MSF Holland/UCL/LSHTM	Opened Jan 2017, results Mar 2021	Belarus, South Africa, Uzbekistan	
STREAM Stage 2	NCT02409290	MCEZHkPro v. JLvCEZHPro v. JLvCZHK v. local DR regimen [DR]	III	1155	IUATLD/MRC/USAID/TBA	Opened Apr 2016, results Apr 2021		
C211	NCT02354014	PK/Safety: 4 age strata J + OBR [DR, ages 0 - 18] [HIV-]	II	60	Janssen	Opened May 2016, results Mar 2021	India, Philippines, Russia, South Africa	
endTB	NCT02754765	9JLzMZ v. 9JLzCLzZ v. 9JLzDLzZ v. 9DCMZ v. 24OBR [DR, quinolone sensitive]	III	750	MSF France/Harvard	Opened Dec 2016, results Sep 2020	Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru	
A5343 DELIBERATE	NCT02583048	pK DDI QT 6J v. 6D v. 6JD + OBR [DR] [HIV-/+]	II	84	ACTG (Maertens/Dooley)	Opened Aug 2016, accrual 20, results 2017		
P1108	n/a	PK/safety: dose-range J + OBR [DR, 0-18 yrs, HIV-/+]	II	72	IMPAACT (Hesseling)	Opens Jun 2017	Haiti, India, South Africa	
NC-007 ZeNIX	NCT03086486	4 arms: 6 or 2 LZD ₁₂₀₀ or 600 [double blind] + J _{200/100} + Pa ₂₀₀ [DR, ≥14, HIV+/-]	III	180	TB Alliance	Opens Oct 2017, results Jan 2021		
Nitroimidazoles: Pretomanid - PA-824 - Pa (TB Alliance)								
n/a	NCT01674218	PaM QT study [5 arms, crossover, healthy volunteers]	I	75	NAID/DMID	Completed Dec 2012, results pending		
A5306	NCT01571414	PK: Pa with LPV/r, EFV, RIF [HIV-]	I	48	ACTG (Dooley)	Results CROI 2013 188LB, AAC 2014	RIF + EFV ↓ [Pa], LPV/r no effect	

Drug(s)	Trial Name	NCT / WHO #	Arms	Ph	N	Group(s)	Status	Results
NC-002	NCT01498419		SSCC: 2 Pa (100 v. 200 mg) MZ v. 2HRZE [DS + DR]	II	230	TB Alliance	Lancet Mar 2015	
NC-003	NCT01691534		2 wk EBA JPaZ, JPaZC, JPaC, JZC, Z, C	IIa	105	TB Alliance	Results CROI 2014 97LB, AJRCCM Jan 2015	BPaZ best, mod QT effect, C no activity
NC-005	NCT02193776		SSCC: J(400 mg/d x14d, 200 mg tiw)PaZ v. J(200 mg/d)PaZ (+ M in DR) v. HRZE	IIb	240	TB Alliance	FU to M24 ongoing, results CROI 2017 LB724	BPaMZ + BPaZ had highest BA; low AEs in 8 wks
NC-006 STAND	NCT02342886		4Pa _{100/200} MZ v. 6Pa ₁₀₀ MZ v. 6Pa ₂₀₀ MZ v. 2HRZE/4HR [DS, DR 6Pa ₂₀₀ MZ only]	III	284	TB Alliance	Completed early, results Q3 2017	
APT	NCT02256696		12 wk: 2Pa ₂₀₀ BHZ/1Pa ₂₀₀ BH v. 2Pa ₂₀₀ RHZ/1Pa ₂₀₀ RH v. 2HRZE/1HR [DS]	II	183	JHU/UCT (Dooley/Dawson)	N=28, reopening May 2017 after Pa hold	
NIX-TB	NCT02333799		6JPa ₂₀₀ LZD (600 mg bid) [single arm, XDR]	III	200	TB Alliance	Opened Mar 2015, primary results Oct 2018	Interim results CROI 2017 80LB, effective, 27% AEs
TB-PRACTECAL	NCT02589782		2 stage: 6JPaMLz v. 6JPaLzC v. 6JPaLz v. 24OBR [DR, XDR]	II/III	630	MSF Holland (Nyang'wa)	Opened Jan 2017, results Mar 2021	Belarus, South Africa, Uzbekistan
NC-007 ZeNIX	NCT03086486		4 arms: 6 or 2 LZD _{1200 or 600} [double blind] + J _{200/100} + Pa ₂₀₀ [DR, ≥14, HIV+/-]	III	180	TB Alliance	Opens Oct 2017, results Jan 2021	
Nitroimidazoles: Delamanid - OPC-67683 - D (Otsuka)								
Trial 204	NCT00685360		D (200 mg bid v. 100 mg bid) + OBR [DR]	II	481	Otsuka	Completed	NEJM Jun 2012, Eur Resp J Jun 2013
Trial 213	NCT01424670		2D (100 mg bid)+OBR / 4D (200 mg qd)+OBR v. 6placebo+OBR [DR]	III	511	Otsuka	Completed June 2016, results 2017	
Trial 232	NCT01856634		18d PK: 4 peds cohorts D <25, 25, 50, 100 mg bid + OBR x 10 d [DR]	I	36	Otsuka	Opened July 2013, results 2018	Cape Town/Philippines
Trial 233	NCT01859923		6M PK/Safety: 4 peds cohorts D <25, 25, 50, 100 mg bid + OBR x 6 mo [DR]	II	36	Otsuka	Opened Aug 2013, results 2020	Cape Town/Philippines
MDR-END	NCT02619994		9 or 12D + Lx _{750/1000} + Lz _{600x2M+300} + Z v. 24OBR [DR, quinolone sensitive]	II	238	Seoul Nat. Univ. Hospital	Opened Jan 2016, results Dec 2019	
endTB	NCT02754765		9JLzMZ v. 9JLzCLxZ v. 9JLzDLxZ v. 9DCMZ v. 24OBR [DR, quinolone sensitive]	III	750	MSF France/Harvard	Opened Dec 2016, results Sep 2020	Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru
A5343 DELIBERATE	NCT02583048		pK DDI QT 6J v. 6D v. 6JD + OBR [DR] [HIV-/+]	II	84	ACTG (Maertens/Dooley)	Opened Aug 2016, results 2017 (N=20)	
IMPAACT 2005	n/a		PK/safety: single arm 6D + (oral)OBR [DR, 0 - 18, HIV-/+]	I/II	48	IMPAACT (Dooley)	Opens 2018, results Apr 2021	Botswana, India, South Africa, Tanzania
A5356	n/a		6D(100 bid)+LZD(300 qd/600 qd/1200 qod) + OBR (oral) v. 6D + OBR (inj.) [DR]	IIa	240	ACTG (Benson)	Opens Dec 2017	
A5300B / 12003B	n/a		PHOENIX LTBI: 6D v. 9H [DR contacts, age 6 and up] [HIV-/+]	III	3452	ACTG/IMPAACT	Opens Q1 2018	
Oxazolidinones: Sutezolid - PNU-100480 - U (Pfizer → Sequella)								
n/a	NCT00909990		Safety/WBA U (100, 300, 600, 1200 mg bid) x 14d, 28d +/- Z d 27-28	I	59	Pfizer	Completed	
n/a	NCT01225640		2 wk EBA + WBA U (600 mg bid v. 1200 mg qd) v. HRZE	EBA	59	Pfizer	Results IAS 2012 THLB02, PLOS Apr 2014	1200 mg qd > 600 mg bid, ↑ LFTs
A5289	n/a		2-stage dose-range open label: UHRZ v. UHTZ v. HRZE [DS only] [HIV-/+]	II	182	ACTG (Luetkemeyer)	On hold (Sep 2016)	
Oxazolidinones: Linezolid - LZD - Lz (Pfizer)								
J-1310-026-523	NCT01994460		LZD (600 mg/d, 2 wk v 4 wk) + 2HRZ/4HR v. 2HRZE/4RH [DS only] [HIV-]	III	429	Seoul Nat. Univ. Hospital	Opened Jan 2014, results end 2016	
LIN-CL001	NCT02279875		2 wk EBA/Safety LZD (1200 qd, 600 bid, 600 qd, 300 qd) [DS only]	EBA	113	TB Alliance	Opened Nov 2014, results Feb 2017	New dose strategies tested in study extension
NIX-TB	NCT02333799		6BPa ₂₀₀ LZD (600 mg bid) [single arm, XDR]	III	200	TB Alliance	Opened Mar 2015, primary results Oct 2018	Interim results CROI 2017 80LB, effective, 27% AEs
NExT-5001	NCT02454205		6-9LzJLxZ(H or Eth or Ter) v. 6-8KMZ(Eth or Ter)/16-18MZ(Eth or Ter) [DR]	II/III	300	UCT/Stellenbosch (Dheda)	Opened Oct 2015, results Jan 2019	
MDR-END	NCT02619994		9 or 12D + Lx _{750/1000} + Lz _{600x2M+300} + Z v. 24OBR [DR, quinolone sensitive]	II	238	Seoul Nat. Univ. Hospital	Opened Jan 2016, results Dec 2019	
TB-PRACTECAL	NCT02589782		2 stage: 6JPaMLz v. 6JPaLzC v. 6JPaLz v. 24OBR [DR, XDR]	II/III	630	MSF Holland (Nyang'wa)	Opened Jan 2017, results Mar 2021	Belarus, South Africa, Uzbekistan
endTB	NCT02754765		9JLzMZ v. 9JLzCLvZ v. 9JLzDLvZ v. 9DCMZ v. 24OBR [DR, quinolone sensitive]	III	750	MSF France/Harvard	Opened Dec 2016, results Sep 2020	Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru
A5356	n/a		6D(100 bid)+LZD(300 qd/600 qd/1200 qod) + OBR (oral) v. 6D + OBR (inj.) [DR]	IIa	240	ACTG (Benson)	Opens Dec 2017	
NC-007 ZeNIX	NCT03086486		4 arms: 6 or 2 LZD _{1200 or 600} [double blind] + J _{200/100} + Pa ₂₀₀ [DR, ≥14, HIV+/-]	III	180	TB Alliance	Opens Oct 2017, results Jan 2021	
Iminophenazines: Clofazimine - Lamprene - CFZ - C (Novartis)								
NC-003	NCT01691534		2 wk EBA JPaZ, JPaZC, JPaC, JZC, Z, C	EBA	105	TB Alliance	Results CROI 2014 97LB, AJRCCM Jan 2015	BPaZ best, mod QT effect, C no activity
STREAM Stage 1	ISRCTN78372190		4MCEZHkPro/SMCZE v. local DR regimen [DR]	III	400	IUATLD/MRC/DFID/USAID	Closed to accrual Jun 2015, results Q2 2018	
TB-PRACTECAL	NCT02589782		2 stage: 6JPaMLz v. 6JPaLzC v. 6JPaLz v. 24OBR [DR, XDR]	II/III	630	MSF Holland/UCL/LSHTM	Opened Jan 2017, results Mar 2021	Belarus, South Africa, Uzbekistan
STREAM Stage 2	NCT02409290		MCEZHkPro v. JLxCEZHk v. JLxCEZHk v. local DR regimen [DR]	III	1155	IUATLD/MRC/USAID/TBA	Opened Apr 2016, results Apr 2021	
CLAM320B2202	2015-004440-19		C (50 or 100 mg qd) + OBR v. OBR [DR]	II/III	380	Novartis	Opened Apr 2016, results Apr 2021	Lithuania/Latvia/Russia/Peru/Philippines/RSA/Thailand
endTB	NCT02754765		9JLzMZ v. 9JLzCLvZ v. 9JLzDLvZ v. 9DCMZ v. 24OBR [DR, quinolone sensitive]	III	750	MSF France/Harvard	Opened Dec 2016, results Sep 2020	Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru
A5362 Clo-FAST	n/a		2 stage: (4C ₅₀ v. 4C ₁₀₀ v. 4placebo) + 4HRZE / 2placebo v. 2placebo v. 2HR	IIc	400	ACTG (Metcalfe)	Opens April 2017, follow up to M18	
Ethylene diamines: SQ-109 - Q (Sequella)								
SQ109-01	NCT01218217		EBA Q (75 v. 150 v. 300 mg qd) ± R	EBA	90	EDCTP/PanACEA	Completed 2012, JAC Jan 2015	Safe/tolerable, no QT signal, 2C19 induction
MAMS-TB-01	NCT01785186		HR ₃₅ ZE v. HRZQ v. HR ₂₀ ZQ v. HR ₂₀ ZM v. HRZE	II	372	EDCTP/PanACEA	Completed Q1 2015, results CROI 2015 95LB	HRZQ + HR ₂₀ ZQ arms dropped Mar 2014
n/a	n/a		6Q + OBR v. OBR [DR]	IIb/III	140	Infectex/Sequella	Results Mar 2017 (7 sites Russia)	Safe/tolerable, 80% 6M SCx v. 61% controls
Imidazopyridines: Q203 - Telecibec (Quorient)								
n/a	n/a		PK, safety, dose range: single + multiple doses [healthy volunteers]	I	?	Infectex/Quorient	Opened March 2016, results pending	
Q203-TB-PI-US001	n/a		PK, safety, dose range: single doses [healthy volunteers]	Ia	56	Quorient US	Opened Aug 2015, completed Feb 2016	
Q203-TB-PI-US002	NCT02858973		PK, safety, dose range: multiple doses [healthy volunteers, placebo, blinded]	Ib	24	Quorient US	Opened August 2016, results end 2017	
n/a	n/a		To be decided	Iia	??	Quorient/PANACEA	To open by end 2017	Univ. of Munich
3,4 Carbostyriil Derivative: OPC-167832 (Otsuka)								
n/a	n/a		PK, safety, dose range, EBA studies	I-II	?	Otsuka	4 studies to open Oct 2016 through 2017	
Benzothiazinones: PBTZ169 (Nearmedic Plus LLC)								
PBTZ169-Z00-C01-1	NCT03036163		PK, safety, dose range healthy volunteers	I	35	Nearmedic Plus	Opened Jan 2016, results Nov 2016	
Beta-lactams/Carbapenems: Faropenem - F_{AC} (with amoxicillin/clavulanate), Meropenem - M_{AC} (with amoxicillin/clavulanate)								
TASK-001	NCT02349841		2 wk EBA: M (2 gm IV tid) + AC tid v. F (600 mg po tid) + AC tid v. HRZE	EBA	46	Task (Diacon)/GSK	Opened Sep 2014, results CPTR Apr 2016	Meropenem _{AC} showed EBA, F _{AC} low exposures
Faropenem-TB	NCT02381470		5d EBA: F (400 mg po tid) + AC (500/125 mg po tid) v. H ₃₀₀ v. Z (2 gm) [DS]	EBA	28	NUH Singapore (Paton)	Opens July 2017, results Mar 2018	Philippines, Singapore
Thiazolidines: Nitazoxanide - NTZ - N (Romark)								
NTZ001	NCT02684240		2 wk EBA: N (1000 mg bid) + HRZE v. HRZE [DS, HIV-]	EBA	30	Cornell/GHESKIO (Pape)	Opened Feb 2016, results Mar 2017	Haiti
2 Month Treatment Shortening Strategies [DS]								
TRUNCATE-TB	n/a		MAMS 2(multiple new regimens) v. 2HRZE/4HR	II/III	900	MRC/UCL (Paton/Phillips)	Opens Q1 2017, results 2019	Thailand, Indonesia, Philippines, Singapore
4 Month Treatment Shortening Strategies [Minimal DS < 16 yrs]								
SHINE	ISRCTN63579542		2HRZ(E)/2HR v. 2HRZE/4HR [DS, < 16 yrs, minimal disease, HIV-/+]	III	1200	MRC/UCL/DFID (Gibb)	Opened Q3 2016, results 2020	India, Uganda, South Africa, Zambia